European Generic Makers Wary Of Marketing Exclusivity For Pediatric Testing

Law360, New York (April 20, 2005, 12:00 AM EDT) -- European generic drug makers have launched a campaign to amend European Union plans to offer six months of extended marketing exclusivity for drugs that undergo pediatric testing.

The European Generic Medicines Association, which represents the region’s generics makers, has acknowledged that some additional market exclusivity may be “acceptable” to offset costs of pediatric testing.

However, the trade group claims an automatic six-month extension for all pediatric testing would be a mistake, leading to higher drug costs for consumers while brand-name drug makers benefit unfairly from the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.